Amylyx Pharmaceuticals (AMLX) Receivables - Other (2022 - 2026)

Amylyx Pharmaceuticals has reported Receivables - Other for 5 years, with the latest figure at $500000.0 in Q2 2026.

• On a quarterly basis, Receivables - Other rose 400.0% year-over-year to $500000.0 in Q2 2026; TTM through Jun 2026 was $500000.0, a 400.0% increase from a year earlier, with the FY2025 full-year figure at $100000.0, changed 0.0% from the prior year.
• Receivables - Other was $500000.0 for Q2 2026 at Amylyx Pharmaceuticals, up from $100000.0 in the prior quarter.
• The five-year high for Receivables - Other was $800000.0 in Q2 2023, with the low at $100000.0 in Q3 2023.
• Average Receivables - Other over 5 years is $253333.3, with a median of $100000.0 recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Receivables - Other sank 87.5% in 2024, then jumped 400.0% in 2026.
• Over 5 years, Receivables - Other stood at $500000.0 in 2022, then changed by 0.0% to $500000.0 in 2023, then tumbled by 80.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then surged by 400.0% to $500000.0 in 2026.
• The last three Receivables - Other figures came in at $500000.0 (Q2 2026), $100000.0 (Q1 2026), and $100000.0 (Q4 2025), per Business Quant data.